Kousuke Kanemoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kousuke Kanemoto has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Toshihiko Fukuchi
Fukuchi Clinic Kikugawa Japan
2 shared publications- Akihiro Shimotake
Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication - Akiko Yamaguchi
Department of Psychiatry Graduate School of Medicine, Nagoya University Nagoya Japan
1 shared publication - Akio Ikeda
Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication Akira Sengoku
Utano National Hospital
1 shared publication- Alexis Tarrada
CHRU de Nancy, Département de Neurologie, Nancy, France
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70092
Evaluating and Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance: Key Considerations of the Japanese Guideline and Criteria for Clinical Implementation of Evidence
The cross‐national differences in automobile driving precautions stated in psychotropic drug package inserts primarily reflect regulatory policies and insufficient evaluation method standardization until recent years, rather than intrinsic ethnic differences. In January 2025, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued the Criteria for Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance. These criteria were published as an appendix to an earlier guideline for evaluating these effects published in December 2022. These guidelines and criteria, developed by the authors, provide methods for evaluating the effects of psychotropic drugs. However, these are not intended to assess the fitness of an individual patient to drive. The MHLW guideline and criteria recommend a tiered approach for assessing clinically meaningful driving impairment. Adverse events affecting alertness, such as drowsiness, caused by psychotropic drugs on driving performance are more frequent during the initial treatment stages and dose escalation. Therefore, evaluating the effects of psychotropic drugs on driving performance requires careful consideration of the persistence of clinically meaningful impairment. Additionally, understanding the magnitude and duration of such effects is crucial for selecting appropriate treatments and offering effective guidance to patients. The MHLW criteria categorize the effects of psychotropic drugs on driving performance into four levels based on their magnitude and duration. Furthermore, the MHLW criteria could help to determine which clinical trials are necessary to evaluate the persistence of clinically meaningful impairment. Namely, the MHLW criteria could be used to structure the substantial evidence needed for evaluating the effects on driving performance for approval applications and clinical implementation.
- 11 February 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70092
Open AccessEvaluating and Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance: Key Considerations of the Japanese Guideline and Criteria for Clinical Implementation of Evidence
The cross‐national differences in automobile driving precautions stated in psychotropic drug package inserts primarily reflect regulatory policies and insufficient evaluation method standardization until recent years, rather than intrinsic ethnic differences. In January 2025, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued the Criteria for Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance. These criteria were published as an appendix to an earlier guideline for evaluating these effects published in December 2022. These guidelines and criteria, developed by the authors, provide methods for evaluating the effects of psychotropic drugs. However, these are not intended to assess the fitness of an individual patient to drive. The MHLW guideline and criteria recommend a tiered approach for assessing clinically meaningful driving impairment. Adverse events affecting alertness, such as drowsiness, caused by psychotropic drugs on driving performance are more frequent during the initial treatment stages and dose escalation. Therefore, evaluating the effects of psychotropic drugs on driving performance requires careful consideration of the persistence of clinically meaningful impairment. Additionally, understanding the magnitude and duration of such effects is crucial for selecting appropriate treatments and offering effective guidance to patients. The MHLW criteria categorize the effects of psychotropic drugs on driving performance into four levels based on their magnitude and duration. Furthermore, the MHLW criteria could help to determine which clinical trials are necessary to evaluate the persistence of clinically meaningful impairment. Namely, the MHLW criteria could be used to structure the substantial evidence needed for evaluating the effects on driving performance for approval applications and clinical implementation.
- Open Access
- 27 January 2023
- Published by Wiley in Epilepsia Open
- Vol. 8 (1) , 134-145
Prospective multicenter cohort study of possible psychogenic nonepileptic seizure cases—Results at 1‐year follow‐up examinations
Objective: The primary purpose of this prospective multicenter study was to examine clinical and demographic feature differences according to the diagnostic level of psychogenic nonepileptic seizures (PNES) and then clarify whether prognosis may also differ accordingly.Methods: Two hundred forty‐two consecutive patients strongly suspected of having PNES attacks were invited to participate, of whom 52 did not consent or contact was lost. At the 1‐year follow‐up examination, PNES diagnosis was reconsidered in nine patients. In 96 patients, the diagnostic level remained the same (P‐group), with that in 43 considered to be clinically established (CE‐group) and in 42 documented (D‐group). The Qolie‐10 and NDDI‐E questionnaires were examined at both the study entry and the follow‐up examination.Results: Multiple regression analysis of quality of life (QoL) score (n = 173; R2 = 0.374; F = 7.349; P < 0.001) revealed NDDI‐E score (t = −6.402; P < 0.001), age of PNES onset (t = −3.026; P = 0.003), and ethnic minority status (t = 3.068; P = 0.003) as significant contributors. At entry, the P‐group showed the lowest PNES attack frequency (P < 0.000), the lowest rate of antiseizure, antidepressant, and antipsychotic medication (P < 0.000; P = 0.031; P = 0.013, respectively), and the lowest proportion of psychosis (P = 0.046). At follow‐up, PNES attack frequency (P < 0.000), number of admittances to emergency room (P < 0.000), and scores for QoL (P < 0.000) as well as depression (P = 0.004) were found to be significantly improved together with other collateral indicators, such as rate of antiseizure medication prescription (P = 0.001) and psychiatric symptoms (P = 0.03). Multiple regression analysis of a sample limited to patients with intellectual disability (ID) (n = 44; R2 = 0.366; F = 4.493; P = 0.002) revealed continued psychotherapy at follow‐up (t = 2.610, P = 0.013) and successful reduction in antiseizure medication (t = 2.868; P = 0.007) as positively related with improved QoL.Significance: Clinical and the socio‐psychological constellation of possible, clinically established, and documented PNES were found to differ greatly. Unexpectedly, significant effects of the continuous psychotherapeutic intervention were confirmed in PNES patients with ID.
- 27 January 2023
- Published by Wiley in Epilepsia Open
- Vol. 8 (1) , 134-145
Open AccessProspective multicenter cohort study of possible psychogenic nonepileptic seizure cases—Results at 1‐year follow‐up examinations
Objective: The primary purpose of this prospective multicenter study was to examine clinical and demographic feature differences according to the diagnostic level of psychogenic nonepileptic seizures (PNES) and then clarify whether prognosis may also differ accordingly.Methods: Two hundred forty‐two consecutive patients strongly suspected of having PNES attacks were invited to participate, of whom 52 did not consent or contact was lost. At the 1‐year follow‐up examination, PNES diagnosis was reconsidered in nine patients. In 96 patients, the diagnostic level remained the same (P‐group), with that in 43 considered to be clinically established (CE‐group) and in 42 documented (D‐group). The Qolie‐10 and NDDI‐E questionnaires were examined at both the study entry and the follow‐up examination.Results: Multiple regression analysis of quality of life (QoL) score (n = 173; R2 = 0.374; F = 7.349; P < 0.001) revealed NDDI‐E score (t = −6.402; P < 0.001), age of PNES onset (t = −3.026; P = 0.003), and ethnic minority status (t = 3.068; P = 0.003) as significant contributors. At entry, the P‐group showed the lowest PNES attack frequency (P < 0.000), the lowest rate of antiseizure, antidepressant, and antipsychotic medication (P < 0.000; P = 0.031; P = 0.013, respectively), and the lowest proportion of psychosis (P = 0.046). At follow‐up, PNES attack frequency (P < 0.000), number of admittances to emergency room (P < 0.000), and scores for QoL (P < 0.000) as well as depression (P = 0.004) were found to be significantly improved together with other collateral indicators, such as rate of antiseizure medication prescription (P = 0.001) and psychiatric symptoms (P = 0.03). Multiple regression analysis of a sample limited to patients with intellectual disability (ID) (n = 44; R2 = 0.366; F = 4.493; P = 0.002) revealed continued psychotherapy at follow‐up (t = 2.610, P = 0.013) and successful reduction in antiseizure medication (t = 2.868; P = 0.007) as positively related with improved QoL.Significance: Clinical and the socio‐psychological constellation of possible, clinically established, and documented PNES were found to differ greatly. Unexpectedly, significant effects of the continuous psychotherapeutic intervention were confirmed in PNES patients with ID.
- 25 October 2022
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 37 (11)
Electroconvulsive therapy improves psychotic symptoms in patients with dementia with Lewy bodies
Purpose: The aim of this study was to examine the efficacy and safety of electroconvulsive therapy (ECT) for psychotic symptoms of dementia with Lewy bodies (DLB), and also to determine its use as an adaptive criterion.Methods: Eight patients aged 66–83 years old (mean 75.4 ± 5.9 years) diagnosed with probable DLB based on the criteria for DLB and who received ECT between September 2013 and December 2019 at Aichi Medical University were enrolled. The efficacy and safety of ECT were retrospectively examined. Psychotic symptoms were evaluated using the Brief Psychiatric Rating Scale (BPRS), while parkinsonism was evaluated based on Hoehn‐Yahr (HY) stage, with both scores analyzed and compared statistically between before and after ECT. Additionally, a follow‐up survey after undergoing ECT was performed.Results: Two incidents occurred during ECT sessions, arrhythmia in one patient and respiratory arrest in another, both of whom quickly recovered. Following ECT, a significant improvement in BPRS score was noted (p < 0.018, Wilcoxon signed rank test), whereas no significant difference was seen in regard to HY stage (p = 0.059). Follow‐up survey findings obtained after ECT (mean observation period 15.9 ± 16.7 months), showed that all eight patients were alive and none had a relapse of psychotic symptoms.Conclusion: The present results suggest that ECT for patients with mild to moderate DLB and drug therapy‐resistant psychotic symptoms is safe, well tolerated and effective. We consider it worth considering as a DLB therapeutic option.
- 25 October 2022
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 37 (11)
Electroconvulsive therapy improves psychotic symptoms in patients with dementia with Lewy bodies
Purpose: The aim of this study was to examine the efficacy and safety of electroconvulsive therapy (ECT) for psychotic symptoms of dementia with Lewy bodies (DLB), and also to determine its use as an adaptive criterion.Methods: Eight patients aged 66–83 years old (mean 75.4 ± 5.9 years) diagnosed with probable DLB based on the criteria for DLB and who received ECT between September 2013 and December 2019 at Aichi Medical University were enrolled. The efficacy and safety of ECT were retrospectively examined. Psychotic symptoms were evaluated using the Brief Psychiatric Rating Scale (BPRS), while parkinsonism was evaluated based on Hoehn‐Yahr (HY) stage, with both scores analyzed and compared statistically between before and after ECT. Additionally, a follow‐up survey after undergoing ECT was performed.Results: Two incidents occurred during ECT sessions, arrhythmia in one patient and respiratory arrest in another, both of whom quickly recovered. Following ECT, a significant improvement in BPRS score was noted (p < 0.018, Wilcoxon signed rank test), whereas no significant difference was seen in regard to HY stage (p = 0.059). Follow‐up survey findings obtained after ECT (mean observation period 15.9 ± 16.7 months), showed that all eight patients were alive and none had a relapse of psychotic symptoms.Conclusion: The present results suggest that ECT for patients with mild to moderate DLB and drug therapy‐resistant psychotic symptoms is safe, well tolerated and effective. We consider it worth considering as a DLB therapeutic option.
- 1 November 2021
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 92, 195-199
Impact of antiepileptic drugs on simulated driving in patients with epilepsy
- 1 November 2021
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 92, 195-199
Impact of antiepileptic drugs on simulated driving in patients with epilepsy
- Open Access
- 5 October 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 125, 108361
Risk factors for psychological distress in electroencephalography technicians during the COVID-19 pandemic: A national-level cross-sectional survey in Japan
- 5 October 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 125, 108361
Open AccessRisk factors for psychological distress in electroencephalography technicians during the COVID-19 pandemic: A national-level cross-sectional survey in Japan
- 24 August 2021
- Published by Springer Nature
- Vol. 55, 183-208
Psychotic Disorders in Epilepsy: Do They Differ from Primary Psychosis?
Any attempt to compare the definitions of symptoms listed for “primary psychoses” with those adopted in studies of psychoses in patients with epilepsy (PWE) will encounter problems of heterogeneity within both conditions. In this manuscript, five psychotic illnesses listed in Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5), that is, brief psychotic illness, schizophreniform disorder, schizophrenia, delusional disorder, and schizoaffective disorder are compared with postictal (or periictal) and interictal psychotic disorders in PWE. After examining definitions of primary psychoses, definitions of psychoses adopted in the papers dealing with postictal and interictal psychoses are summarized. Further, diagnostic criteria of five types of psychotic disorders in PWE proposed in 2007 by Krishnamoorthy et al. are also discussed, which include postictal psychosis, comorbid schizophrenia, iatrogenic psychosis caused by antiepileptic drugs (AEDs) (AED-induced psychotic disorder: AIPD), and forced normalization. Evidently, a comparison between postictal psychosis and schizophrenia is pointless. Likewise, schizophrenia may not be an appropriate counterpart of forced normalization and AIPD, given their acute or subacute course. Based on these preliminary examinations, three questions are selected to compare primary psychoses and psychoses in PWE: Is postictal psychosis different from a brief psychotic disorder? Does epilepsy facilitate or prevent the development of psychosis or vice versa? Is interictal psychosis of epilepsy different from process schizophrenia? In conclusion, antagonism between psychosis and epileptic seizures in a later stage of active epilepsy seems not to be realized without reorganization of the nervous system promoted during an earlier stage. Both genetic predisposition and the summated effects of epileptic activity must be taken into consideration as part of a trial to explain interictal psychosis. Interictal psychosis is an aggregate of miscellaneous disorders, that is, co-morbid schizophrenia, AED-induced psychotic disorders, forced normalization, and “epileptic” interictal psychosis. Data are lacking to conclude whether differences exist between process schizophrenia and “epileptic” interictal psychosis in terms of negative symptoms, specific personal traits, and the “bizarre-ness” of delusory-hallucinatory contents. These discussions may shed light on the essence of process schizophrenia, thus allowing it stand out and receive increased focus.
- 24 August 2021
- Published by Springer Nature
- Vol. 55, 183-208
Psychotic Disorders in Epilepsy: Do They Differ from Primary Psychosis?
Any attempt to compare the definitions of symptoms listed for “primary psychoses” with those adopted in studies of psychoses in patients with epilepsy (PWE) will encounter problems of heterogeneity within both conditions. In this manuscript, five psychotic illnesses listed in Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5), that is, brief psychotic illness, schizophreniform disorder, schizophrenia, delusional disorder, and schizoaffective disorder are compared with postictal (or periictal) and interictal psychotic disorders in PWE. After examining definitions of primary psychoses, definitions of psychoses adopted in the papers dealing with postictal and interictal psychoses are summarized. Further, diagnostic criteria of five types of psychotic disorders in PWE proposed in 2007 by Krishnamoorthy et al. are also discussed, which include postictal psychosis, comorbid schizophrenia, iatrogenic psychosis caused by antiepileptic drugs (AEDs) (AED-induced psychotic disorder: AIPD), and forced normalization. Evidently, a comparison between postictal psychosis and schizophrenia is pointless. Likewise, schizophrenia may not be an appropriate counterpart of forced normalization and AIPD, given their acute or subacute course. Based on these preliminary examinations, three questions are selected to compare primary psychoses and psychoses in PWE: Is postictal psychosis different from a brief psychotic disorder? Does epilepsy facilitate or prevent the development of psychosis or vice versa? Is interictal psychosis of epilepsy different from process schizophrenia? In conclusion, antagonism between psychosis and epileptic seizures in a later stage of active epilepsy seems not to be realized without reorganization of the nervous system promoted during an earlier stage. Both genetic predisposition and the summated effects of epileptic activity must be taken into consideration as part of a trial to explain interictal psychosis. Interictal psychosis is an aggregate of miscellaneous disorders, that is, co-morbid schizophrenia, AED-induced psychotic disorders, forced normalization, and “epileptic” interictal psychosis. Data are lacking to conclude whether differences exist between process schizophrenia and “epileptic” interictal psychosis in terms of negative symptoms, specific personal traits, and the “bizarre-ness” of delusory-hallucinatory contents. These discussions may shed light on the essence of process schizophrenia, thus allowing it stand out and receive increased focus.
- 1 November 2019
- Published by Elsevier in Epilepsy & Behavior
- Vol. 100 (Pt A) , 106528
Epileptic psychoses are underrecognized by French neurologists and psychiatrists
- 1 November 2019
- Published by Elsevier in Epilepsy & Behavior
- Vol. 100 (Pt A) , 106528
Epileptic psychoses are underrecognized by French neurologists and psychiatrists
- Open Access
- 1 February 1998
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 64 (2) , 245-248
Characteristics and treatment of temporal lobe epilepsy with a history of complicated febrile convulsion
This study aimed to examine the close correlation between complicated febrile convulsions (CFC) and medial temporal lobe epilepsy and to delineate characteristics of temporal lobe epilepsy with CFC. Patients with temporal lobe epilepsy were divided into those with a prior episode of CFC (n=52), those with febrile convulsions other than CFC, and those witout either (n=345). Clinical constellations, neuroimaging, drug resistance, and effects of temporal lobectomy of the three groups were compared. A close association between CFC and temporal lobe epilepsy was confirmed. The salient features of temporal lobe epilepsy with CFC were early age at onset of habitual seizures (about 10 years), the predominance of autonomic auras, and a high incidence of MRI evidence of unilateral medial temporal sclerosis. Patients with temporal lobe epilepsy with prior CFC had an excellent outcome after surgery, by contrast with an unfavourable response to drug therapy. The surgical results were discouraging in patients with temporal lobe epilepsy without history of any febrile convulsions and without solid brain tumours. These results indicate surgical intervention as the choice of therapy in a substantial number of patients with temporal lobe epilepsy with a history of CFC.
- 1 February 1998
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 64 (2) , 245-248
Open AccessCharacteristics and treatment of temporal lobe epilepsy with a history of complicated febrile convulsion
This study aimed to examine the close correlation between complicated febrile convulsions (CFC) and medial temporal lobe epilepsy and to delineate characteristics of temporal lobe epilepsy with CFC. Patients with temporal lobe epilepsy were divided into those with a prior episode of CFC (n=52), those with febrile convulsions other than CFC, and those witout either (n=345). Clinical constellations, neuroimaging, drug resistance, and effects of temporal lobectomy of the three groups were compared. A close association between CFC and temporal lobe epilepsy was confirmed. The salient features of temporal lobe epilepsy with CFC were early age at onset of habitual seizures (about 10 years), the predominance of autonomic auras, and a high incidence of MRI evidence of unilateral medial temporal sclerosis. Patients with temporal lobe epilepsy with prior CFC had an excellent outcome after surgery, by contrast with an unfavourable response to drug therapy. The surgical results were discouraging in patients with temporal lobe epilepsy without history of any febrile convulsions and without solid brain tumours. These results indicate surgical intervention as the choice of therapy in a substantial number of patients with temporal lobe epilepsy with a history of CFC.
- 1 January 1994
- Published by Elsevier in Journal of Epilepsy
- Vol. 7 (3) , 171-177
Age at onset of epilepsy and aura sensations: Understanding aura sensations from the developmental viewpoint
- 1 January 1994
- Published by Elsevier in Journal of Epilepsy
- Vol. 7 (3) , 171-177
Age at onset of epilepsy and aura sensations: Understanding aura sensations from the developmental viewpoint
- Open Access
- 1 January 1991
- Published by The Japan Epilepsy Society in Journal of the Japan Epilepsy Society
- Vol. 9 (2) , 105-112
Recurrent Utterance as a Verbal Automatism in a Patient with Temporal Lobe Epilepsy; Analysis of Ictal Depth-EEG.
- 1 January 1991
- Published by The Japan Epilepsy Society in Journal of the Japan Epilepsy Society
- Vol. 9 (2) , 105-112
Open AccessRecurrent Utterance as a Verbal Automatism in a Patient with Temporal Lobe Epilepsy; Analysis of Ictal Depth-EEG.